Andreas Kungl,Jason Slingsby,Tiziana Adage,Angelika Rek
申请号：
US13395128
公开号：
US20120288474A1
申请日:
2010.09.13
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.
